Biomolecules are increasingly vital in healthcare. Their intrinsic complexity makes it difficult to commercialize biomolecule products, and results in products that are fragile and inconvenient to use. There is an urgent need to streamline the path for next-generation biomolecule products to reach markets, while also enhancing their quality, reliability, and convenience.
Our vision is to advance equitable healthcare by optimizing biomolecule product development and enhancing their downstream accessibility, reliability, and convenience. Our AI-driven approach creates tailor-made, mechanically fine-tuned biostability materials that precisely meet unique needs. This empowers our customers with the sophisticated technologies they need to bring their biomolecules to market more efficiently and effectively.
Our Approach
We breathe new life into biomolecule products, unlocking their fullest potentials in broader application areas. Our AI-driven high throughput screening platform allows for rapid development of proprietary biostability materials. We use FDA-approved ingredients to solve problems affecting the biomolecule product supply chain, ranging from manufacturing to administration. Our technology integrates easily into existing workflows, lessening the need for additional equipment or training.
How It Works
Discover the power of AEMS Corp's revolutionary ADM™ (Agent Delivery Matrix™): a new class of functional biostability materials with access a vast range of chemical and material properties. We combine well-known FDA-approved ingredients in a proprietary molecular network without the need for specialty components. Our custom-built high throughput screening platform is optimized to ensure exceptional performance and versatility by meticulously considering the specific applications of each biomolecule: Incorporating biomolecules into ADM™ can improve manufacturing operations, provide greater thermal stability, or overcome conventional concentration and viscosity limitations: all with the convenience of rapid AI prototyping.
Benefits
We streamline the process of bringing your biomolecular technologies to market with enhanced reliability and the support of our dedicated team of engineers. Our expertise overcomes traditional barriers to manufacturing, formulation, shelf stability, and administration. Partnering with us enables you to overcome logistical challenges, allowing you to focus on what matters most.
Founders
W. Scott Compel, PHD
CEO
Scott is a chemist turned materials engineer who excels creating new and innovative material platforms. He discovered the groundbreaking RAMETRIC materials during his PhD work and secured funding to uncover its unique molecular structure, which was recently featured on the cover of Cell Reports Physical Science. During his postdoctoral work at Lawrence Livermore National Lab, he formulated new carbon fiber composite materials for Direct Ink Write 3D printing and wrote tailored software for a custom-built 3D printer. Scott conceived AEMS Corp's revolutionary platform technology, the Agent Delivery Matrix (ADM), and utilizes his 3D printing background to develop advanced robotic techniques that automate ADM discovery.
Nicholas Colella, PHD
Executive Chairman
Nick Colella, formerly a Senior VP at Tessera, Inc., played a pivotal role in revitalizing the company and taking it public in 2003. Nick has served as a CTO in energy storage and communication firms, led innovative defense projects at Lawrence Livermore National Laboratory, and co-founded nChip, which was later acquired by Flextronics. Nick helped establish Carnegie Mellon's National Robotics Engineering Center, chairing its Advisory Board. He actively supports startups in semiconductors, energy, and biomedicine and serves on advisory boards and corporate boards.
Alexander R. Hendricks, PhD
Alex is a biological chemist with a background in high-throughput screening, enzyme engineering, and cellular assays. At AEMS Corp, he spearheads the discovery and pursuit of commercial applications. Alex has played a pivotal role in steering the company from academic discoveries towards applications in biotechnology. As the driving force behind innovation and productization, he excels at identifying applications for a versatile platform technology in the absence of a defined path. Alex is a budding entrepreneur actively engaged with the Colorado startup community and is committed to sharing his expanding skillset.
Partnerships
At AEMS Corp, we believe in the transformative power of collaboration. We have established partnerships with world-renowned experts who share our vision of enhancing biotechnology and making it more accessible and convenient for all. We are actively seeking additional partners to combine our knowledge and resources in tackling the industry's most pressing challenges. Together, we aim to deliver cutting-edge solutions that make a lasting impact. Join us as we forge a path toward a brighter, more equitable future alongside our esteemed partners.
Press
Featured
Contact Us
